Abstract:Abstract Disclosure: V. Master: None. J. Syeda: None. S. Charatz: None. D. Reidy: None. K. Clary: None. Introduction: Indeterminate thyroid nodules pose a significant clinical challenge due to their potential risk of malignancy. The Afirma GSC has emerged as a valuable tool for the non-invasive management of these nodules. However, its real-world performance in community healthcare settings remains poorly understood. Aim: Comparison of GSC performance in a community healthcare setting to the validation study (VS) metrics. Method: A retrospective study was conducted in a community endocrine practice, where 91 Afirma GSC samples were obtained from patients who had either suspicious cytology or atypia of undermined significance (AUS) between 1/1/2021 and 12/31/2022. Ten samples were excluded due to insufficient material. Surgical pathology was used as the gold standard for diagnosis. Molecular benign results without surgical pathology were considered true negatives, and 2 unoperated patients with suspicious results were excluded from analysis. We calculated observed positive predictive value (oPPV) and observed specificity (oSP) to account for these exclusions. Non-invasive follicular neoplasm with papillary-like features is considered malignant. The prevalence of thyroid cancer in the study population was 19%. Results are compared to previously published VS of 191 samples. Result: Our study showed a higher accuracy of 89% of the Afirma GSC in our community healthcare setting, with a sensitivity (SN) of 93%, oSP of 88%, oPPV of 63%, and negative predictive value (NPV) of 98%. In comparison, the VS had a SN of 91%, SP of 68%, PPV of 47%, NPV of 96%, and accuracy of 74%. Additionally, our study showed a higher benign call rate (BCR) of 70% compared to 54% in the VS. Conclusion: Our study provides evidence of the real-world performance of the Afirma GSC and supports its use as a non-invasive tool for the management of indeterminate thyroid nodules. Better oSP and oPPV are suggestive of higher yield of cancers for resected nodules based on suspicious GSC. References: Nasr CE, Andrioli M, Endo M, Harrell RM, Livhits MJ, Osakwe I, Polavarapu P, Siperstein A, Wei S, Zheng X, Jiang R, Hao Y, Huang J, Klopper JP, Kloos RT, Kennedy G, Angell TE. Real World Performance of The Afirma Genomic Sequencing Classifier (GSC) - A Meta-analysis. J Clin Endocrinol Metab. 2022 Dec 6:dgac688. doi: 10.1210/clinem/dgac688. Epub ahead of print. PMID: 36470585. Patel KN, Angell TE, Babiarz J, Barth NM, Blevins T, Duh QY, Ghossein RA, Harrell RM, Huang J, Kennedy GC, Kim SY, Kloos RT, LiVolsi VA, Randolph GW, Sadow PM, Shanik MH, Sosa JA, Traweek ST, Walsh PS, Whitney D, Yeh MW, Ladenson PW. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules. JAMA Surg. 2018 Sep 1;153(9):817-824. doi: 10.1001/jamasurg.2018.1153. PMID: 29799911; PMCID: PMC6583881. Presentation: Thursday, June 15, 2023

Outcomes of cytologically indeterminate thyroid nodules managed with Genomic Sequencing Classifier

THU678 Real-world Performance Of Afirma Genomic Sequencing Classifier (GSC) In A Community Healthcare Setting

Outcomes of Indeterminate Thyroid Nodules Managed Nonoperatively after Molecular Testing

Diagnostic accuracy of Afirma Gene Expression Classifier, Afirma Gene Sequencing Classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis

Performance of the AmpliSeq NGS Panel in Thyroid Nodules with Indeterminate Cytology

The negative outlook: Long‐term follow up of ThyroSeq negative and low‐risk nodules

Evolutionary analysis of indeterminate cytology and risk of malignancy in a thyroid nodule unit.

ThyroSeq overview on indeterminate thyroid nodules: An institutional experience

Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules

Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology

Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review

Utility of a Multigene Testing for Preoperative Evaluation of Indeterminate Thyroid Nodules: A Prospective Blinded Single Center Study in China

The value of NGS-based multi-gene testing for differentiation of benign from malignant and risk stratification of thyroid nodules

Prevalence of cancer and the benign call rate of afirma gene classifier in 18 F-Fluorodeoxyglucose positron emission tomography positive cytologically indeterminate thyroid nodules

Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules

Highly Accurate NGS-based Multi-Gene Testing in the Diagnosis of Thyroid Nodules with Indeterminate Cytology.

Next generation sequence-based targeted somatic mutation analysis in thyroid nodules with pathologically diagnosed as indeterminate cytology

Molecular Profiling for Bethesda III to VI Nodules: Results of a Multicenter International Retrospective Study

Risk stratification of ThyroSeq results in indeterminate thyroid lesions: A single‐institution experience of clinicopathologic correlation with cytologic findings

Multiplatform molecular test performance in indeterminate thyroid nodules

Diagnostic Value of TI-RADS Classification System and Next Generation Genetic Sequencing in Indeterminate Thyroid Nodules